Literature DB >> 24686052

Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Lisa A Lewis1, David M Vu, Dan M Granoff, Sanjay Ram.   

Abstract

Neisseria meningitidis utilizes capsular polysaccharide, lipooligosaccharide (LOS) sialic acid, factor H binding protein (fHbp), and neisserial surface protein A (NspA) to regulate the alternative pathway (AP) of complement. Using meningococcal mutants that lacked all four of the above-mentioned molecules (quadruple mutants), we recently identified a role for PorB2 in attenuating the human AP; inhibition was mediated by human fH, a key downregulatory protein of the AP. Previous studies showed that fH downregulation of the AP via fHbp or NspA is specific for human fH. Here, we report that PorB2-expressing quadruple mutants also regulate the AP of baby rabbit and infant rat complement. Blocking a human fH binding region on PorB2 of the quadruple mutant of strain 4243 with a chimeric protein that comprised human fH domains 6 and 7 fused to murine IgG Fc enhanced AP-mediated baby rabbit C3 deposition, which provided evidence for an fH-dependent mechanism of nonhuman AP regulation by PorB2. Using isogenic mutants of strain H44/76 that differed only in their PorB molecules, we confirmed a role for PorB2 in resistance to killing by infant rat serum. The PorB2-expressing strain also caused higher levels of bacteremia in infant rats than its isogenic PorB3-expressing counterpart, thus providing a molecular basis for increased survival of PorB2 isolates in this model. These studies link PorB2 expression with infection of infant rats, which could inform the choice of meningococcal strains for use in animal models, and reveals, for the first time, that PorB2-expressing strains of N. meningitidis regulate the AP of baby rabbits and rats.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24686052      PMCID: PMC4019150          DOI: 10.1128/IAI.01517-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  106 in total

1.  Identification of the hypervirulent lineages of Neisseria meningitidis, the ST-8 and ST-11 complexes, by using monoclonal antibodies specific to NmeDI.

Authors:  Heike Claus; Hanne Weinand; Matthias Frosch; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.

Authors:  Gregory R Moe; Patricia Zuno-Mitchell; Samantha N Hammond; Dan M Granoff
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  CD46 in meningococcal disease.

Authors:  Linda Johansson; Anne Rytkonen; Peter Bergman; Barbara Albiger; Helena Källström; Tomas Hökfelt; Birgitta Agerberth; Roberto Cattaneo; Ann-Beth Jonsson
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

4.  Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.

Authors:  Jo Anne Welsch; Gregory R Moe; Raffaella Rossi; Jeannette Adu-Bobie; Rino Rappuoli; Dan M Granoff
Journal:  J Infect Dis       Date:  2003-11-19       Impact factor: 5.226

5.  Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia.

Authors:  Joyce S Plested; Shannon L Harris; J Claire Wright; Philip A Coull; Katherine Makepeace; Margaret-Anne J Gidney; Jean-Robert Brisson; James C Richards; Dan M Granoff; E Richard Moxon
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226

6.  Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Authors:  Shannon L Harris; Adam Finn; Dan M Granoff
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

7.  Neisseria meningitidis RTX proteins are not required for virulence in infant rats.

Authors:  Stanislav Forman; Irena Linhartova; Radim Osicka; Xavier Nassif; Peter Sebo; Vladimir Pelicic
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

8.  Ontogeny of complement regulatory proteins - concentrations of factor h, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults.

Authors:  P F de Paula; J E Barbosa; P R Junior; V P L Ferriani; M R D O Latorre; V Nudelman; L Isaac
Journal:  Scand J Immunol       Date:  2003-11       Impact factor: 3.487

9.  NadA, a novel vaccine candidate of Neisseria meningitidis.

Authors:  Maurizio Comanducci; Stefania Bambini; Brunella Brunelli; Jeannette Adu-Bobie; Beatrice Aricò; Barbara Capecchi; Marzia Monica Giuliani; Vega Masignani; Laura Santini; Silvana Savino; Dan M Granoff; Dominique A Caugant; Mariagrazia Pizza; Rino Rappuoli; Marirosa Mora
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

10.  Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Authors:  Vega Masignani; Maurizio Comanducci; Marzia Monica Giuliani; Stefania Bambini; Jeannette Adu-Bobie; Beatrice Arico; Brunella Brunelli; Alessandro Pieri; Laura Santini; Silvana Savino; Davide Serruto; David Litt; Simon Kroll; Jo Anne Welsch; Dan M Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  9 in total

1.  Resistance of Neisseria meningitidis to human serum depends on T and B cell stimulating protein B.

Authors:  Maike G Müller; Nina E Moe; Phillip Q Richards; Gregory R Moe
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

2.  Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Authors:  Serena Giuntini; Rolando Pajon; Sanjay Ram; Dan M Granoff
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

3.  Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic.

Authors:  Jutamas Shaughnessy; David M Vu; Rahi Punjabi; Judit Serra-Pladevall; Rosane B DeOliveira; Dan M Granoff; Sanjay Ram
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

4.  Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Heather Stefek; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

5.  Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Authors:  Eduardo Lujan; Elizabeth Partridge; Serena Giuntini; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 6.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

7.  The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection.

Authors:  Ana Antunes; Meriem Derkaoui; Aude Terrade; Mélanie Denizon; Ala-Eddine Deghmane; Josef Deutscher; Isabel Delany; Muhamed-Kheir Taha
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

Review 8.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

9.  Difference in virulence between Neisseria meningitidis serogroups W and Y in transgenic mice.

Authors:  Lorraine Eriksson; Bianca Stenmark; Ala-Eddine Deghmane; Sara Thulin Hedberg; Olof Säll; Hans Fredlund; Paula Mölling; Muhamed-Kheir Taha
Journal:  BMC Microbiol       Date:  2020-04-15       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.